|
| Study | Target | ID | Purpose | Status |
|
| Mitotane with or without IMC-A12 in treating patients with recurrent, metastatic, or primary adrenocortical cancer that cannot be removed by surgery | IGF1R | NCT00778817 | This randomized phase II trial compares the combination of mitotane and IMC-A12 with mitotane alone in the treatment of recurrent, metastatic, or primary adrenocortical cancer that cannot be removed by surgery | Recruiting |
|
| A study of OSI-906 in patients with locally advanced or metastatic adrenocortical carcinoma (GALACCTIC) | IGF1R | NCT00924989 | A multicenter, randomized, double-blind, placebo-controlled, phase III study of single-agent OSI-906 in patients with locally advanced/metastatic adrenocortical carcinoma who received at least 1 but no more than 2 prior drug regimens | Ongoing not recruiting |
|
| Phase II trial of ZD1839 (Iressa) in patients with nonresectable adrenocortical carcinoma | VEGFR | NCT00215202 | This phase II trial investigates the effect of Iressa in patients with nonresectable adrenocortical cancer who have previously been treated with one other form of systemic therapy (either Mitotane or chemotherapy). | Completed |
|
| Phase II Study of Axitinib (AG-013736) With Evaluation of the VEGF-Pathway in Metastatic, Recurrent or Primary Unresectable Adrenocortical Cancer | Multikinase | NCT01255137 | To evaluate the effectiveness of axitinib in individuals who have adrenocortical cancer that is inoperable and has not responded to standard treatments | Recruiting |
| (i) VEGFR |
| (ii) PDGFR |
| (iii) KIT |
|
| Sunitinib in Refractory Adrenocortical Carcinoma (SIRAC) | Multikinase | NCT00453895 | The primary objective of this trial is to estimate the response (defined as progression-free survival of ≥12 weeks) rate associated with Sunitinib treatment in patients advanced ACC progressing after cytotoxic chemotherapy | Unknown |
| (i) VEGFR |
| (ii) PDGFR |
| (iii) KIT |
|
| Sorafenib Plus Paclitaxel in adreno-cortical-cancer patients (PAXO) | Multikinase | NCT00786110 | The aim of this phase II trial is to evaluate the clinical benefit and toxicity of the combination of Sorafenib plus metronomic chemotherapy in patients with locally advanced or metastatic ACC who progressed after first or second line chemotherapy. | Unknown |
| (i) RAF |
| (ii) VEGFR |
| (iii) PDGFR |
| (iv) KIT |
|
| Clinical trial of Dovitinib in first-line metastatic or locally advanced non-resectable adrenocortical carcinom | FGFRs | NCT01514526 | Non-randomized, phase II clinical trial, that investigates the use of Dovitinib in adult patients with metastatic or locally advanced non-resectable adrenocortical carcinoma, confirmed histologically | Recruiting |
|
| Cixutumumab in treating patients with relapsed or refractory solid tumors | IGF1R | NCT00831844 | Phase II trial that studies the side effects and how well cixutumumab works in treating patients with relapsed or refractory solid tumors, including ACC | Recruiting |
|
